LEADER 04933nam 22007815 450 001 9910437852203321 005 20230810211049.0 010 $a3-642-38919-8 024 7 $a10.1007/978-3-642-38919-1 035 $a(CKB)3710000000078836 035 $a(EBL)1636594 035 $a(OCoLC)871223964 035 $a(SSID)ssj0001086174 035 $a(PQKBManifestationID)11699543 035 $a(PQKBTitleCode)TC0001086174 035 $a(PQKBWorkID)11055124 035 $a(PQKB)10939470 035 $a(DE-He213)978-3-642-38919-1 035 $a(MiAaPQ)EBC1636594 035 $a(PPN)176112839 035 $a(EXLCZ)993710000000078836 100 $a20131220d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aChallenges and Opportunities for Respiratory Syncytial Virus Vaccines /$fedited by Larry J. Anderson, Barney S. Graham 205 $a1st ed. 2013. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2013. 215 $a1 online resource (405 p.) 225 1 $aCurrent Topics in Microbiology and Immunology,$x2196-9965 ;$v372 300 $aDescription based upon print version of record. 311 $a3-642-38918-X 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aRespiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease -- Clinical and Epidemiologic Features of Respiratory Syncytial Virus -- Influence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity -- Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins -- Respiratory Syncytial Virus and Reactive Airway Disease -- Human Genetics and Respiratory Syncytial Virus Disease: Current Findings and Future Approaches -- Innate Immune Responses to Respiratory Syncytial Virus Infection -- The Adaptive Immune Response to Respiratory Syncytial Virus -- Respiratory Syncytial Virus Mechanisms to Interfere with Type 1 Interferons -- Host Gene Expression and Respiratory Syncytial Virus Infection -- Consequences of Immature and Senescent Immune Responses for Infection with Respiratory Syncytial Virus -- Respiratory Syncytial Virus Disease:  Prevention and Treatment -- Live-Attenuated Respiratory Syncytial Virus Vaccines -- Subunit and Virus-Like Particle Vaccine Approaches for Respiratory Syncytial Virus -- Gene-Based Vaccine Approaches for Respiratory Syncytial Virus -- Bovine Model of Respiratory Syncytial Virus Infection -- The Cotton Rat S. hispidus Model of Respiratory Syncytial Virus Infection -- The Mouse Model of Respiratory Syncytial Virus Disease -- Human Airway Epithelial Cell Cultures for Modeling Respiratory Syncytial Virus Infection -- Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. 330 $aAlthough respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure. The success of RSV immune prophylaxis and the availability of ever more powerful tools to study the immune response and pathogenesis of disease, combined with the ability to construct a wide variety of vaccines using different vaccine platforms, give us grounds to believe that an RSV vaccine is within reach. This book brings together in one source what is currently known about the virus: its clinical and epidemiologic features; the host response and pathogenesis of the disease; vaccines, vaccine platforms, and treatment; and animal and tissue culture models of RSV infection. It is designed to organize the critical information relevant to RSV vaccine development, facilitate the assimilation of data, and speed progress toward producing a safe and effective vaccine. 410 0$aCurrent Topics in Microbiology and Immunology,$x2196-9965 ;$v372 606 $aVirology 606 $aPharmacology 606 $aDiseases 606 $aRespiratory organs$xDiseases 606 $aPediatrics 606 $aVirology 606 $aPharmacology 606 $aDiseases 606 $aPneumology 606 $aPediatrics 615 0$aVirology. 615 0$aPharmacology. 615 0$aDiseases. 615 0$aRespiratory organs$xDiseases. 615 0$aPediatrics. 615 14$aVirology. 615 24$aPharmacology. 615 24$aDiseases. 615 24$aPneumology. 615 24$aPediatrics. 676 $a615.372 702 $aAnderson$b Larry J$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aGraham$b Barney S$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437852203321 996 $aChallenges and Opportunities for Respiratory Syncytial Virus Vaccines$92502979 997 $aUNINA LEADER 02023oas 2200637 a 450 001 9910229831203321 005 20251105213014.0 035 $a(OCoLC)69387812 035 $a(CONSER) 2009236963 035 $a(CKB)110978978382105 035 $a(EXLCZ)99110978978382105 100 $a20060525b19822002 uy a 101 0 $aeng 135 $aurbn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAnnual review of banking law /$fCenter for Banking Law Studies, Boston University School of Law 210 $aBoston $cWarren, Gorham & Lamont$d1982-©2002 300 $aPublished: [Stoneham, Mass.?] : Butterworth Legal Publishers, 1988-1995; [Charlottesville, Va.] : Michie, 1996-1997; [New York, NY] : Lexis Law Publishing, 1998-2001; Newark, NJ : LexisNexis, 2002. 311 08$a0739-2451 531 0 $aAnnu. rev. bank. law 606 $aBanking law$zUnited States$vPeriodicals 606 $aBanking law$2fast$3(OCoLC)fst00826811 607 $aUnited States$2fast$1https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq 608 $aPeriodicals.$2fast 615 0$aBanking law 615 7$aBanking law. 676 $a346.73/082 676 $a347.30682 712 02$aBoston University.$bCenter for Banking Law Studies. 712 02$aMorin Center for Banking Law Studies 712 02$aMorin Center for Banking and Financial Law Studies 712 02$aBoston University.$bMorin Center for Banking and Financial Law. 712 02$aWilliam S. Hein & Company 801 0$bUVL 801 1$bUVL 801 2$bOCLCQ 801 2$bOCLCS 801 2$bNDO 801 2$bCUD 801 2$bNDO 801 2$bOCLCQ 801 2$bOCLCF 801 2$bOCLCQ 801 2$bVT2 801 2$bUUM 801 2$bCLU 801 2$bLDP 801 2$bTXQ 801 2$bOCLCL 801 2$bOCLCQ 906 $aJOURNAL 912 $a9910229831203321 996 $aANNUAL review of banking law$9681741 997 $aUNINA